Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil hits one-week low as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
September 23, 2024 5:11 AM EDTBofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $191.00 price target on Ascendis Pharma (NASDAQ: ASND).
The analyst comments "We hosted an expert pediatric endocrinologist to discuss his views on ASNDs TransCon CNP in achondroplasia (ACH) following the recent topline ph 3 readout (see our Sep 16th note). Overall, our KOL was encouraged by the stat sig AGV... More
